Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).
Publication/Presentation Date
11-1-2003
Abstract
The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.
Volume
92
Issue
9
First Page
1091
Last Page
1094
ISSN
0002-9149
Published In/Presented At
Ashby, D. T., Aymong, E. A., Tcheng, J. E., Grines, C. L., Cox, D. A., Mehran, R., Garcia, E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Lansky, A. J., Stone, G. W., & CADILLAC Trial (2003). Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). The American journal of cardiology, 92(9), 1091–1094. https://doi.org/10.1016/j.amjcard.2003.06.005
Disciplines
Medicine and Health Sciences
PubMedID
14583362
Department(s)
Department of Medicine
Document Type
Article